MarginsXMarginsX
Home › Markets › Health Care › ALGS

Aligos Therapeutics Inc. (ALGS)

ALGS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.66
-20.95% on the day
Market cap
$10.4M
Nano cap
Revenue · 2025
$2.2M
-39.5% on 2024
Net income · 2025
-$24.2M
-1106.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1799448/000119312526092614/0001193125-26-092614-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerALGS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001799448

Financials · 2025

LineValue
Revenue$2.2M
Net income-$24.2M
Operating income-$88.0M
Net margin-1106.7%
Operating margin-4024.9%
Revenue growth-39.5%
Cash$18.3M
Total assets$88.5M
P/E (computed)Net income was not positive
P/S (computed)4.7×

Warning signs

Cash runway
5.5 months
$31.1M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed November 6, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Our current operating plan and projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report."
10-Q 2026-11-06
Cash and burn$31.1M cash; operating cash flow -$17.1M a quarter.Report 2026-09-30
Shares outstanding12,496,956 (2026-11-03).Cover page 2026-11-03
Reverse splits, 3 years1; latest 1-for-25 on 2024-08-19Source 2024-08-19
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-23
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 6,248,478 shares at the 2026-11-13 price; the latest SEC cover count is 12,496,956 as of 2026-11-03. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.8M-$21.9M$1.5M$31.1MNo debt tags$5.8M10-Q 2026-11-06
Q2 2026
2026-06-30
$0-$1.5M-$24.9M$30.4MNo debt tags$3.7M10-Q 2026-08-06
Q1 2026
2026-03-31
$2.8M-$23.0M-$23.1M$30.0MNo debt tags$4.7M10-Q 2026-05-07
Q4 2025
2025-12-31
$169K-$19.9M-$21.7M$18.3MNo debt tags$2.2M10-K 2026-03-05
Q3 2025
2025-09-30
$741K-$31.5M-$24.3M$41.9MNo debt tags$2.6M10-Q 2026-11-06
Q2 2025
2025-06-30
$965K-$15.9M-$15.5M$18.7MNo debt tags$3.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$311K$43.1M-$20.9M$73.8MNo debt tags$3.2M10-Q 2026-05-07
Q4 2024
2024-12-31
$606K-$82.2M-$18.4M$37.0MNo debt tags$3.6M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-48.4%
1 month-61.9%
3 months-69.0%
Year to date-77.5%
1 year-65.4%
From 52-week high-84.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
INTSIntensity Therapeutics Inc.$3.07-0.32%$10.1M
SCLXScilex Holding Company$1.25-12.59%$10.6M
TCRXTScan Therapeutics Inc.$0.1451-9.65%$9.2M
BCDABioCardia Inc.$0.7901-4.92%$12.0M
INABIN8bio Inc.$0.8160-0.49%$8.8M
DYAIDyadic International Inc.$0.3200-2.14%$12.8M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M
PASGPassage Bio Inc.$4.13-2.82%$13.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier